Regarding the situation in Moselle, in a context where the South African variant is significantly present but without an increase in its prevalence over the last four weeks, the HAS recommends at this stage, to continue to favor access to vaccines for which there is data in favor of maintaining a high level of efficacy against the so-called "South African" variant. These are the BioNTech / Pfizer and Moderna vaccines, on the one hand, and the Janssen vaccine, on the other hand, once it becomes available.
In this very specific epidemiological context in these territories, the HAS recommends respecting a period of 3 to 4 weeks between the two doses for mRNA vaccines.
The HAS also recommends the establishment, in Moselle, of access to the professionals authorized in town to the above vaccines.
HAS recommends that these strategies be deployed or continued over the next few weeks and that the situation be reassessed quickly. It will continue to monitor the effectiveness of different vaccines against variants, the strategies deployed at the international level as well as its work on the relevance of a strategy differentiated according to the prevalence of the different variants.
- Recommendation
- Europe
- France
- COVID-19 variants
- COVID-19
